Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;54(6):2716-9.
doi: 10.1128/AAC.01797-09. Epub 2010 Mar 22.

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

Michael R Jacobs  1 , Caryn E Good, Anne R Windau, Saralee Bajaksouzian, Donald Biek, Ian A Critchley, Helio S Sader, Ronald N Jones
Affiliations

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

Michael R Jacobs et al. Antimicrob Agents Chemother. 2010 Jun.

Abstract

The in vitro activity of ceftaroline against 891 pneumococci collected in 2008 from 22 centers in the United States was investigated. Ceftaroline was the most potent agent tested, with the MICs being <0.008 to 0.5 microg/ml and the MIC(90)s being <0.008 to 0.25 microg/ml against 11 prevailing serotypes. The overall rates of susceptibility were as follows: penicillin G, 86.2%; ceftriaxone, 90.7%; cefuroxime, 70.1%; erythromycin, 61.6%; clindamycin, 79.2%; levofloxacin, 99.4%; and vancomycin, 100%. Serotype 19A isolates were the least susceptible. These results support the use of ceftaroline for the treatment of pneumococcal infections, including those caused by pneumococci resistant to other agents.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Distribution of pneumococcal serotypes isolated from adults and children (n = 891).
FIG. 2.
FIG. 2.
Distribution of ceftaroline MICs (in μg/ml), by serotype.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andes, D., and W. A. Craig. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383. - PMC - PubMed
    1. Centers for Disease Control and Prevention. 2008. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998-2005. MMWR Morb. Mortal. Wkly. Rep. 57:144-148. - PubMed
    1. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Corey, R., M. Wilcox, G. Talbot, T. Baculik, and D. Thye. 2008. CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI), abstr. L-1515a. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.

Publication types

MeSH terms